Nexstim Plc announces the start of patient enrolment in the supplementary Phase III Trial in Stroke Rehabilitation with its NBT system

Helsinki, Finland: 7 March 2017 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system (NBT® system), announces that it has enrolled the first patients in its supplemental Ph III clinical trial in stroke rehabilitation, known as E-FIT (ELECTRIC FIELD NAVIGATED 1HZ RTMS FOR POST-STROKE MOTOR RECOVERY TRIAL) at the Rancho Los Amigos National Rehabilitation Center, Downey, California, USA.

As previously announced, this clinical trial is designed to supplement the completed Ph III NICHE trial. The supplemental trial will be conducted at five clinical sites in the U.S.A. and will include a total of 60 subjects. All sites participating in E-FIT trial also participated in the completed NICHE trial. Nexstim expects that the E-FIT trial to be completed in Q1 2018 and to file for FDA clearance by end of April 2018. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

More info on Nexstim's website.


Next > Nexstim Plc announces signing of an Independent Selling Representative Agreement in the US with Surgical Solutions, Inc

Previous > Avantium launches its initial public offering on Euronext Amsterdam and Euronext Brussels